263 related articles for article (PubMed ID: 20518616)
1. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
Olsson AG
Expert Opin Pharmacother; 2010 Jul; 11(10):1715-26. PubMed ID: 20518616
[TBL] [Abstract][Full Text] [Related]
2. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Yiu KH; Cheung BM; Tse HF
Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
[TBL] [Abstract][Full Text] [Related]
3. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
[TBL] [Abstract][Full Text] [Related]
4. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
[TBL] [Abstract][Full Text] [Related]
7. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
8. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Parhofer KG
Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of niacin.
Kamanna VS; Kashyap ML
Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
[TBL] [Abstract][Full Text] [Related]
10. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
[TBL] [Abstract][Full Text] [Related]
11. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
Schima SM; Maciejewski SR; Hilleman DE; Williams MA; Mohiuddin SM
Expert Opin Pharmacother; 2010 Apr; 11(5):731-8. PubMed ID: 20210682
[TBL] [Abstract][Full Text] [Related]
12. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
Bays H; Shah A; Dong Q; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2011 Apr; 65(4):436-45. PubMed ID: 21401833
[TBL] [Abstract][Full Text] [Related]
13. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
[TBL] [Abstract][Full Text] [Related]
14. Important considerations for treatment with dietary supplement versus prescription niacin products.
Backes JM; Padley RJ; Moriarty PM
Postgrad Med; 2011 Mar; 123(2):70-83. PubMed ID: 21474895
[TBL] [Abstract][Full Text] [Related]
15. HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin.
Olsson AG
Nutr Metab Cardiovasc Dis; 2010 Oct; 20(8):553-7. PubMed ID: 20739153
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of extended-release niacin with laropiprant.
Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
[TBL] [Abstract][Full Text] [Related]
17. High-density lipoprotein cholesterol: current perspective for clinicians.
Whayne TF
Angiology; 2009; 60(5):644-9. PubMed ID: 19240106
[TBL] [Abstract][Full Text] [Related]
18. The resurgence of niacin: from nicotinic acid to niaspan/laropiprant.
Markel A
Isr Med Assoc J; 2011 Jun; 13(6):368-74. PubMed ID: 21809737
[TBL] [Abstract][Full Text] [Related]
19. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
20. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
